Duchenne UK news

Duchenne UK CEO joins the ABPI's Patient Advisory Council

Duchenne UK CEO and co-founder Emily Crossley has joined the Association of the British Pharmaceutical Industry's (ABPI) new Patient Advisory Council to help represent the patient's voice in the UK pharmaceutical industry.

The ABPI is the trade body for the pharmaceutical industry in the UK. It has among its members all the biggest pharmaceutical companies, and its members produce almost all the medicines prescribed on the NHS. It is large and influential, and Emily will be taking part at the highest level of the organisation.

Duchenne UK has a history of working positively with the pharmaceutical industry involved in Duchenne muscular dystrophy (DMD) treatment development through initiatives such as Project HERCULES, making sure patient priorities are heard. Emily’s position on this new Patient Advisory Council is an opportunity to not only champion DMD at the top of industry and government, but to continue this good work with the whole sector.

For more information, you can read the ABPI’s press release here.

Published on 7 September 2021

Share this article